{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:43:56Z","timestamp":1789609436731,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cefazolin elastomeric infusers are commonly used in outpatient settings with peripherally inserted central catheters (PICCs) or mid-line catheters to treat various infections. However, data on the safety of cefazolin elastomeric infusers administered via a peripheral IV catheter (PIVC) are limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the safety and complications of outpatient cefazolin elastomeric infusers via PIVC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective case series study was conducted, reviewing patients treated with cefazolin elastomeric infuser via PIVC between January 2018 and December 2022 in our institution. The primary outcomes assessed were PIVC-related complications using visual infusion phlebitis (VIP) score, including catheter-related bacteraemia and readmissions within 30\u2005days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 415 patients aged \u226518\u2005years were treated with cefazolin elastomeric infuser through PIVC during the 5\u2005year study period. On average, each patient required two PIVCs during outpatient treatment, amounting to 870 PIVCs in total. Of these, 85% (n\u200a=\u200a352) of patients received cefazolin 6\u2005g daily. The majority were treated for cellulitis (83%) with a median duration of 5\u2005days. No complications (VIP score\u200a=\u200a0) were observed in 88.3% (n\u200a=\u200a768) of catheters. The incidence of VIP scores of 1, 2 and \u22653 was 8.9% (n\u200a=\u200a37), 4.1% (n\u200a=\u200a17) and 0% (n\u200a=\u200a0), respectively. There were no statistically significant differences in age, sex, comorbidity or diagnosis between participants with a VIP score of 0 and those with a VIP score of \u22651. The incidence of complications including catheter leakage, blockage and dislodgement was low (2.3%, 1.6% and 2%, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Outpatient cefazolin elastomeric infusers administered via PIVC were well tolerated and safe.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf169","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:37:32Z","timestamp":1758613052000},"source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of continuous cefazolin infusion via peripheral intravenous catheter (PIVC) for outpatient therapy: a brief report"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4365-8799","authenticated-orcid":false,"given":"Hubert","family":"Chan","sequence":"first","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Ambulatory Care Medicine, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solly","family":"Joseph","sequence":"additional","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Ambulatory Care Medicine, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Tran","sequence":"additional","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Ambulatory Care Medicine, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Geriatrics, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"School of Clinical Medicine, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Dotel","sequence":"additional","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Infectious Diseases, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J J","family":"Ngian","sequence":"additional","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Ambulatory Care Medicine, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Geriatrics, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"School of Clinical Medicine, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin S","family":"Ong","sequence":"additional","affiliation":[{"name":"Bankstown-Lidcombe Hospital , Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Ambulatory Care Medicine, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"Department of Geriatrics, Bankstown-Lidcombe Hospital, Bankstown, Sydney, New South Wales ,","place":["Australia"]},{"name":"School of Clinical Medicine, University of New South Wales , Sydney, New South Wales ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2025092304264014300_dlaf169-B1","doi-asserted-by":"publisher","first-page":"20499361231199582","DOI":"10.1177\/20499361231199582","article-title":"Exploring the advancements of Australian OPAT","volume":"10","author":"Lai","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"2025092304264014300_dlaf169-B2","author":"Hospital In The Home (HITH) Society Australasia Ltd"},{"key":"2025092304264014300_dlaf169-B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciy745","article-title":"2018 Infectious Diseases Society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025092304264014300_dlaf169-B4","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.12968\/bjon.2016.25.8.S15","article-title":"Indications for peripheral, midline and central catheters: summary of the MAGIC recommendations","volume":"25","author":"Moureau","year":"2016","journal-title":"Br J Nurs"},{"key":"2025092304264014300_dlaf169-B5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamainternmed.2021.6844","article-title":"Safety and outcomes of midline catheters vs peripherally inserted central catheters for patients with short-term indications: a multicenter study","volume":"182","author":"Swaminathan","year":"2022","journal-title":"JAMA Intern Med"},{"key":"2025092304264014300_dlaf169-B6","doi-asserted-by":"publisher","first-page":"ofad024","DOI":"10.1093\/ofid\/ofad024","article-title":"Comparing complication rates of midline catheter vs peripherally inserted central catheter. A systematic review and meta-analysis","volume":"10","author":"Urtecho","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2025092304264014300_dlaf169-B7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jhm.12995","article-title":"Integrated versus nonintegrated peripheral intravenous catheter in hospitalized adults (OPTIMUM): a randomized controlled trial","volume":"18","author":"Rickard","year":"2023","journal-title":"J Hosp Med"},{"key":"2025092304264014300_dlaf169-B8","author":"Therapeutic Guidelines"},{"key":"2025092304264014300_dlaf169-B9","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s15010-018-1126-4","article-title":"Outpatient parenteral antibiotic therapy in a suburban tertiary referral centre in Australia over 10 years","volume":"46","author":"Li","year":"2018","journal-title":"Infection"},{"key":"2025092304264014300_dlaf169-B10","doi-asserted-by":"publisher","first-page":"2049936119882847","DOI":"10.1177\/2049936119882847","article-title":"Twice daily cefazolin is effective for treatment of serious methicillin-sensitive Staphylococcus aureus infection in an outpatient parenteral antimicrobial therapy program","volume":"6","author":"Birrell","year":"2019","journal-title":"Ther Adv Infect Dis"},{"key":"2025092304264014300_dlaf169-B11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/antibiotics11010045","article-title":"Stability of antimicrobials in elastomeric pumps: a systematic review","volume":"11","author":"Fern\u00e1ndez-Rubio","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025092304264014300_dlaf169-B12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3138\/jammi.2018-0039","article-title":"Continuous cefazolin infusion versus cefazolin plus probenecid for the ambulatory treatment of uncomplicated cellulitis: a retrospective cohort study","volume":"4","author":"Landry","year":"2019","journal-title":"J Assoc Med Microbiol Infect Dis Can"},{"key":"2025092304264014300_dlaf169-B13","doi-asserted-by":"publisher","first-page":"dlaa033","DOI":"10.1093\/jacamr\/dlaa033","article-title":"Cannula complications using elastomeric infusers in hospital in the home","volume":"2","author":"Ryan","year":"2020","journal-title":"JAC Antimicrob Resist"},{"key":"2025092304264014300_dlaf169-B14","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1111\/jan.14565","article-title":"Peripheral intravenous catheter non-infectious complications in adults: a systematic review and meta-analysis","volume":"76","author":"Marsh","year":"2020","journal-title":"J Adv Nurs"},{"key":"2025092304264014300_dlaf169-B15","doi-asserted-by":"publisher","first-page":"e20210398","DOI":"10.1590\/1980-220X-REEUSP-2021-0398en","article-title":"Risk factors for peripheral intravenous catheter-related phlebitis in adult patients","volume":"56","author":"Sim\u00f5es","year":"2022","journal-title":"Rev Esc Enferm USP"},{"key":"2025092304264014300_dlaf169-B16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2025092304264014300_dlaf169-B17","doi-asserted-by":"publisher","first-page":"ofac105","DOI":"10.1093\/ofid\/ofac105","article-title":"Safety and effectiveness of high-dose cefazolin in patients with high body weight: a retrospective cohort study","volume":"9","author":"Ryu","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025092304264014300_dlaf169-B18","first-page":"18","article-title":"Phlebitis: treatment, care and prevention","volume":"107","author":"Higginson","year":"2011","journal-title":"Nurs Times"},{"key":"2025092304264014300_dlaf169-B19","doi-asserted-by":"publisher","first-page":"CD007798","DOI":"10.1002\/14651858.CD007798.pub5","article-title":"Clinically-indicated replacement versus routine replacement of peripheral venous catheters","volume":"1","author":"Webster","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/5\/dlaf169\/64349584\/dlaf169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/5\/dlaf169\/64349584\/dlaf169.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:28:07Z","timestamp":1758616087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf169\/8261926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf169","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,3]]},"article-number":"dlaf169"}}